HC Wainwright Has Negative View of Talphera FY2029 Earnings

Talphera, Inc. (NASDAQ:TLPH) – Equities researchers at HC Wainwright dropped their FY2029 earnings per share estimates for Talphera in a research report issued to clients and investors on Thursday, August 13th. HC Wainwright analyst B. Folkes now forecasts that the company will earn $0.12 per share for the year, down from their prior estimate of $0.13. HC Wainwright has a “Buy” rating and a $3.00 price target on the stock. The consensus estimate for Talphera’s current full-year earnings is ($0.26) per share. HC Wainwright also issued estimates for Talphera’s FY2030 earnings at $0.32 EPS.

Several other equities analysts have also commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Talphera in a research report on Friday, July 17th. Westpark Capital assumed coverage on shares of Talphera in a research report on Thursday, April 30th. They set a “buy” rating and a $3.00 target price on the stock. Zacks Research upgraded Talphera to a “hold” rating in a research report on Monday, June 8th. Finally, Wall Street Zen raised Talphera to a “hold” rating in a research note on Saturday, August 8th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Talphera presently has a consensus rating of “Hold” and an average target price of $3.00.

Talphera Stock Performance

Shares of TLPH opened at $1.21 on Friday. The company’s fifty day moving average is $1.19 and its 200 day moving average is $0.96. Talphera has a fifty-two week low of $0.40 and a fifty-two week high of $1.57. The stock has a market capitalization of $62.80 million, a PE ratio of -4.48 and a beta of 0.69.

Talphera (NASDAQ:TLPH) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.06).

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in TLPH. Group One Trading LLC lifted its holdings in Talphera by 3,224.0% during the 3rd quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock valued at $27,000 after buying an additional 29,500 shares in the last quarter. Dauntless Investment Group LLC bought a new position in Talphera in the 3rd quarter worth about $89,000. Virtu Financial LLC bought a new position in Talphera in the 3rd quarter worth about $29,000. Nantahala Capital Management LLC increased its position in shares of Talphera by 75.3% during the third quarter. Nantahala Capital Management LLC now owns 3,492,519 shares of the company’s stock worth $3,120,000 after acquiring an additional 1,500,000 shares during the period. Finally, AIGH Capital Management LLC increased its position in shares of Talphera by 4.6% during the fourth quarter. AIGH Capital Management LLC now owns 4,661,502 shares of the company’s stock worth $5,314,000 after acquiring an additional 206,957 shares during the period. 37.67% of the stock is currently owned by institutional investors.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.